Disclosed is a stabilized solution preparation of a pharmaceutical GLP-1R antibody fusion protein, comprising therapeutically effective amounts of the GLP-1R antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mM, the final concentration of the surfactant is 0.01%-0.5%, and the pH value of the stabilized solution preparation is from 5.0 to 8Ø The stabilized solution preparation of the present invention can be used in the treatment of diabetes and obesity, and conditions associated therewith.